The standard COPD exacerbation risk definition (≥2 moderate or ≥1 severe exacerbation in the past year) has limited discriminative power.
In both COPDGene and NOVELTY cohorts, considering any moderate or severe exacerbation within the prior two years yielded superior accuracy (AUC up to 0.87) for predicting future exacerbations.
Using rolling two-year exacerbation windows also provided the highest clinical utility across relevant treatment thresholds (5%-30%) for initiating or intensifying therapy.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
